Dateline City:
KENILWORTH, N.J.
Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy
First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, for the first-line
treatment of metastatic non-small cell lung cancer (NSCLC) in adults
whose tumors have high PD-L1 expression (tumor proportion score [TPS] of
50 percent or more) with no EGFR or ALK positive tumor mutations.
Language:
English
Contact:
For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more